NAverting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project
Mult Scler Relat Disord. 2021 Jun 30;54:103107. doi: 10.1016/j.msard.2021.103107
Michela Tinelli 1, Maura Pugliatti 2, Andreea Antonovici 3, Bettina Hausmann 3, Kerstin Hellwig 4, Vinciane Quoidbach 5, Per Soelberg Sørensen 6
Multiple Sclerosis 32 percent less likely among those with more than 32 ng of vitamin D – Dec 2019
- Overview MS and vitamin D
- Multiple Sclerosis treated when use high doses of vitamin D – meta-analysis May 2018
- Multiple Sclerosis: number needed to treat with vitamin D may be as low as 1.3 – Meta-analysis Oct 2013
- Multiple Sclerosis more likely if poor vitamin D genes - 22nd study – Aug 2017
- Multiple Sclerosis relapses cut in half by 100,000 IU of Vitamin D every 2 weeks– RCT 2019
UV and Sunshine reduces MS risk
- Multiple Sclerosis 2X more likely if low winter UV – June 2018
- Multiple Sclerosis half as likely if get plenty of sunshine (not a news item) – March 2018
Other things also help
- Multiple Sclerosis treated by 50,000 IU Vitamin D bi-weekly plus Omega-3 – RCT July 2018
- Multiple Sclerosis 40 percent less likely if consume tinned fish (Vitamin D and Omega-3) – Sept 2019
- Resveratrol treats Multiple Sclerosis and other autoimmune diseases – many studies
- Not a single case of multiple sclerosis in 15,000,000 people (plant-based diets)
High Dose Vitamin D and cofactors
- The use of high dose Vitamin D (Coimbra Protocol) for multiple sclerosis in Germany – 2019
- Successful high dose vitamin D (Coimbra Protocol) should be evaluated – June 2019
- Comparing High-dose vitamin D therapies MS and other health problems
Number of MS studies which are also in other categories
-
20 studies in Genetics - genes can restrict Vitamin D getting to the blood and to the cells 11 studies in Vitamin D Receptor - gene which restricts D from getting to the cells 5 studies in Vitamin D Binding Protein - gene which restricts D from getting to the cells 19 studies in Ultraviolet light - may be even better than Vitamin D in preventing and treating MS 9 studies in Omega-3 - which helps Vitamin D prevent and treat MS - Rate of vitamin D supplementation by Blacks increases 16X after getting Multiple Sclerosis – Feb 2018
- Multiple Sclerosis 42X more likely if light brown skin and smoke (both associated with low vitamin D) – July 2020
- Multiple Sclerosis patients had fewer COVID-19 problems (Note: many MSers take Vitamin D) – April 30, 2021
- UK people with Multiple Sclerosis are 3X more likely to take Vitamin D - Oct 2020
- Multiple Sclerosis relapses cut in half by 100,000 IU of Vitamin D every 2 weeks– RCT 2019
Background and purpose: The recent report on Value-of-Treatment (VoT) project highlights the need for early diagnosis-intervention, integrated, seamless care underpinning timely care pathways and access to best treatments. The VoT-multiple-sclerosis (MS) economic case study analysis aimed to estimate the effectiveness/cost-effectiveness of both early treatment and reducing MS risk factors (e.g. smoking and vitamin D insufficiency).
Methods: A series of decision analytical modellings were developed and applied to estimate the cost-effectiveness of: (1) reducing the conversion from clinically-isolated-syndrome (CIS) to clinically-definite-MS (CDMS); (2) smoking cessation and increase of 25 hydroxyvitamin D (25(OH)D) serum level. Both (1) and (2) considered socioeconomic impact on averted MS disability progression. Costs were reported for societal and healthcare provider perspectives (pending on data across nations; Euros). Effectiveness was expressed as Quality-Adjusted-Life-Years (QALYs) gains. Long term (25, 30, 40,50-years) and short (one-year) timelines were considered for (1) and (2), respectively.
Results: Early treatment was cost-effective for the health care provider and both cost-effective/cost-saving for the society across time-horizons and nations. Smoking cessation and an increase of 25(OH)D in MS patients were both cost-effective/cost-saving across nations.
Conclusions: To the best of our knowledge, our work provides the first economic evidence to base appropriate public health interventions to reduce the MS burden in Europe.
Vitamin D cost-effectively treats Multiple Sclerosis (36 dollar study) – July 2021Printer Friendly PDF this page! Follow this page for updates175 visitors, last modified 09 Jul, 2021, This page is in the following categories (# of items in each category)